STOCK TITAN
  1. Home
  2. News
  3. IGXT

Intelgenx Technologies Corp - IGXT STOCK NEWS

Welcome to our dedicated page for Intelgenx Technologies news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on Intelgenx Technologies stock.

Intelgenx Technologies Corp (IGXT) specializes in advanced drug delivery solutions for pharmaceutical partners worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's proprietary technologies, strategic collaborations, and regulatory progress.

Track critical developments including formulation advancements, clinical trial milestones, manufacturing expansions, and partnership announcements. Our curated collection ensures timely access to verified press releases and objective reporting on IGXT's role in enhancing therapeutic outcomes through innovative delivery systems.

Discover updates spanning key operational areas: regulatory submissions for improved drug formulations, strategic licensing agreements with global partners, and manufacturing scale-up initiatives for optimized production. Bookmark this page for direct access to Intelgenx's official communications and third-party analyses of their pharmaceutical development progress.

News

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

Rhea-AI Summary
IntelGenx Technologies Corp. announces a Loan Agreement with atai Life Sciences AG, involving Additional Term Loans, Conversion Features, Warrants issuance, and related party transactions. atai advances up to US$2 million convertible into 10,810,810 Shares, aiming to beneficially own approximately 67% of the Company's issued and outstanding Shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
News

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

Rhea-AI Summary
IntelGenx Corp. announced a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock at $10.00 per share, aiming to raise $20,000,000. Holders will receive 8% yearly dividends and can convert each share into 20 common shares. The offering aims to support the pending U.S. commercial launch of RizaFilm® and strategic investments in the product pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
News

IntelGenx Launches Preferred Share Regulation A Offering

Rhea-AI Summary
IntelGenx Corp. announced a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock at $10.00 per share, aiming to raise a maximum of $20,000,000. The holders of the Series A Preferred Stock will receive cumulative dividends of $0.20 per share each quarter. The offering is intended to support the upcoming U.S. commercial launch of RizaFilm® and strategic investments in the company's product pipeline and services portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
News

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

Rhea-AI Summary
IntelGenx Corp. (IGXT) announced positive results from a proof-of-concept study evaluating the acceptance and ease of administration of its VetaFilm platform in dogs and cats. The study, conducted in collaboration with the University Prince Edward Island, showed high acceptance rates and ease of administration of VetaFilm FDOFs in both species. Dog owners and cat owners reported that administration of VetaFilm FDOFs was very easy or easy, with a majority identifying it as the preferred method of medication administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

Rhea-AI Summary
IntelGenx Corp. (IGX) announces development and license agreements with Covenant Animal Health, expanding its Animal Health business. Covenant Animal Health will fund development and manufacturing of a VetaFilm®-based drug, giving them exclusive rights to exploit the Product for non-human applications. IntelGenx will receive royalties on worldwide net sales of the Product and manufacture it for clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
partnership
-
News

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

Rhea-AI Summary
IntelGenx Technologies Corp. (IGX) closed a non-brokered private placement with atai Life Sciences AG for US$750,000. Shareholders approved the financing transactions. atai now has the ability to exercise a call option and purchase additional US Units. The participation of atai in the Subsequent atai Subscription and the grant of the Call Option constitute a 'related party transaction' within the meaning of MI 61-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
News

IntelGenx Announces Changes to its Board of Directors

Rhea-AI Summary
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors and the appointment of Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
management
-
News

IntelGenx Announces Shareholder Approval of Financing Transactions

Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) shareholders approve financing transactions with atai Life Sciences AG, including the issuance of common stock and an increase in authorized shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
none
-
News

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Rhea-AI Summary
IntelGenx Corp. (IGX) Announces Phase 2 MONTPARK Trial for Montelukast VersaFilm to Treat Parkinson’s Disease. The trial is approved by Swedish Medical Products Agency and aims to investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. Expected to begin recruiting patients in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) Urges Shareholders to Vote on Key Proposals at Upcoming Special Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IGXT logo
Intelgenx Technologies Corp

OTC:IGXT

IGXT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IGXT Stock Data

29.69M
135.54M
22.4%
Biotechnology
Healthcare
Link
Canada
Montreal